

## Special Issue

# Biomarkers and Clinical Research in Eating Disorders

### Message from the Guest Editor

Eating disorders are severe and disabling disorders affecting individuals of all ages, most frequently commencing in adolescence. The treatment success rates are around 50%, and treatment resistance occurs in 20%. Recent genetic research in anorexia nervosa points to genetic associations with, for example, hyperlipidemia, diabetes, schizophrenia, and OCD, laying the foundation for an improved understanding of the nature of the diseases. However, further research is needed in biology, biomarker and clinical research to advance the field towards improved treatments. Cutting-edge research in recent years, especially genome-wide association studies, has raised hopes of determining the underlying biology of eating disorders. One example is the recent advances in blood-based biomarkers such as increases in cytokines in anorexia nervosa. The aim of this Special Issue is to present research on the psychological and biological pathologies, novel outcomes, or clinical characteristics of eating disorders that may provide clues for improved treatment. We invite original publications, systematic reviews, and case series.

---

### Guest Editor

Dr. Jan Magnus Sjøgren

Institute for Clinical Science, Department of Psychiatry, Umeå University, 901 85 Umeå, Sweden

---

### Deadline for manuscript submissions

closed (22 January 2023)



## Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 4.1  
Indexed in PubMed



[mdpi.com/si/74699](https://mdpi.com/si/74699)

*Journal of Personalized  
Medicine*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://mdpi.com/journal/)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 4.1  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm.mdpi.com)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM)*, ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

---

### Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

#### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).